Clinical trials: Thrombotic Microangiopathies
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Primary Immune Thrombocytopenia (ITP)
Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
The goal of this multicenter, observational, retrospective is to evaluate the standards of use of thrombopoietin receptor agonists (TPO-RA) in adult patients with primary immune thrombocytopenia (ITP), with a particular interest…
- Trial name
- NCT06408324
- Where
- 17 sites in France, Italy and 4 more
- Volunteers
- 275 people
- Sponsor
- European Research Consortium on ITP
Thrombotic Thrombocytopenic Purpura
Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
Multicentric non-randomized phase II opened prospective study (10 centres involved). Primary endpoint: To evaluate the kinetics of B-cell depletion by rituximab and its pharmacokinetics in patients treated with rituximab in…
- Trial name
- PTTritux (NCT00907751)
- Testing
- rituximab
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thrombocytopenia
Managed Access Programs for ETB115, Eltrombopag
The purpose of this registration is to list Managed Access Programs (MAPs) related to ETB115, Eltrombopag
- Trial name
- NCT04837703
- Testing
- Eltrombopag
- Sponsor
- Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
- Trial name
- ADVANCE+ (NCT04225156)
- Testing
- efgartigimod
- Where
- 87 sites in United States, Austria and 16 more
- Volunteers
- 101 people
- Sponsor
- argenx
Thrombotic Microangiopathy
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
The purpose of this compassionate use study, for two patients with thrombotic microangiopathy, is to provide expanded access to patients who have participated in the clinical trial OMS721-TMA-001 and in whom improvement in their…
- Trial name
- NCT02355782
- Testing
- OMS721
- Sponsor
- Michal Nowicki
Idiopathic Thrombocytopenic Purpura
Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology
This study was conducted in conjunction with the 2 phase 3 studies of AMG 531 (20030105 and 20030212) and an open-label extension study (20030213) and compared pretreatment and posttreatment bone marrow samples for the purpose of…
- Trial name
- NCT00861224
- Testing
- No Intervention for Observational Study
- Volunteers
- 10 people
- Sponsor
- Amgen
Immune Thrombocytopenia, Myelodysplastic Syndromes
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia, including immunodeficiencies, constitutional or…
- Trial name
- NCT03469661
- Where
- 6 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Idiopathic Thrombocytopenic Purpura (ITP)
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
The primary purpose of this study is to evaluate the safety of multiple doses of Staphylococcal protein A (PRTX-100) in adult patients with Idiopathic Thrombocytopenia Purpura (ITP).
- Trial name
- NCT00571467
- Testing
- PRTX-100 (Staphylococcal protein A)
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Protalex, Inc.
Mucositis, Graft-versus-host Disease
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
A comparative trial where all patients will receive daily doses of tacrolimus (TAC) until day +60 when tapering will begin, in the absence of graft-versus-host disease (GVHD), and discontinued by day +180.
- Trial name
- NCT00360685
- Testing
- Tac+MTX, TAC + MMF
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Immune Thrombocytopenia
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
It seems reasonable to assume that patients who present significant bleeding symptoms may have different quality of platelets than those without bleeding.
- Trial name
- NCT03377439
- Testing
- Platelet function tests
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Shandong University
Primary Immune Thrombocytopenia
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP).
- Trial name
- NCT05621330
- Testing
- QL0911
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Thrombotic Thrombocytopenic Purpura
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Primary Objective: To evaluate the effect of caplacizumab on prevention of recurrence of aTTP (proportion of participants with a recurrence of aTTP) during the overall study period.
- Trial name
- NCT04074187
- Testing
- Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone)
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Sanofi
Idiopathic Thrombocytopenic Purpura
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study…
- Trial name
- NCT00625443
- Testing
- Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Eisai Inc.
Immune Thrombocytopenia (ITP)
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
- Trial name
- NCT01054443
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shionogi
Purpura, Thrombocytopaenic, Idiopathic
EXTEND (Eltrombopag Extended Dosing Study)
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag…
- Trial name
- EXTEND (NCT00351468)
- Testing
- eltrombopag olamine (SB-497115-GR)
- Where
- 110 sites in United States, Australia and 29 more
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenia, Glucocorticoids
Short-course High-dose Prednisone and Dexamethasone in Children With ITP
Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)
- Conditions
- Immune Thrombocytopenia, Glucocorticoids, Child, Only
- Trial name
- NCT05522465
- Testing
- Prednisone, Dexamethasone
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Fujian Medical University Union Hospital
Purpura, Thrombotic Thrombocytopenic, TTP
A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura
In this study, the investigators want to determine if N-acetylcysteine(NAC), given intravenously, will decrease complications in patients with Thrombotic Thrombocytopenia Purpura (TTP) who are receiving treatment with therapeutic…
- Trial name
- NACinTTP (NCT01808521)
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bloodworks
Immune Thrombocytopenia, Treatment
A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of CM313 in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including…
- Trial name
- 2022-CM313-ITP (NCT05694767)
- Testing
- CM313 Injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thrombocytopenic Purpura
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.
- Trial name
- NCT00117143
- Testing
- Romiplostim
- Volunteers
- 16 people
- Sponsor
- Amgen